8 citations
,
July 1990 in “Archives of Dermatology” A woman had a skin reaction from a cough suppressant, dextromethorphan, which is a new cause of fixed-drug eruption.
March 2024 in “BMC women's health” The levonorgestrel implant increases free testosterone and lowers SHBG more than DMPA-IM and the copper IUD.
14 citations
,
November 2014 in “European journal of medicinal chemistry” Researchers found new potential treatments for conditions related to the androgen receptor, like male hormonal contraception, by testing thousands of compounds.
33 citations
,
January 2016 in “Skin appendage disorders” The document concludes that sexual and psychiatric side effects from 5-alpha-reductase inhibitors are reported, but more high-quality research is needed to understand how often they occur.
2 citations
,
April 2016 in “Journal of The American Academy of Dermatology” Dutasteride more effective than finasteride for hair growth; SM04554 safe and potentially effective for hair loss.
May 1993 in “Drugs & Therapy Perspectives” Formestane is a preferred second-line treatment for advanced breast cancer in postmenopausal women because it's effective and has fewer side effects.
1 citations
,
January 1997 in “Journal of Investigative Dermatology” RU58841, an androgen receptor blocker, significantly increased hair density, thickness, and length in monkeys when applied topically daily for several months.
59 citations
,
February 2021 in “BMJ” High doses of cyproterone acetate increase the risk of brain tumors in women, but the risk decreases after stopping the medication.
21 citations
,
February 2021 in “BMJ case reports” Anabolic steroid users may face higher risk of severe COVID-19.
May 2024 in “Reactions weekly” P-3074 effectively blocks scalp DHT better than oral finasteride.
April 2019 in “Journal of Investigative Dermatology” Testosterone affects androgen receptors and lipid storage in cells, while DHEA does not convert to testosterone or affect these receptors in the same way.
The treatment was not recommended due to limited effectiveness and significant side effects.
31 citations
,
January 1989 in “The Prostate/The prostate” Estradiol and castration reduced prostate cancer development in rats when applied at early stages, but were ineffective after cancer was established.
51 citations
,
May 2013 in “The Journal of Steroid Biochemistry and Molecular Biology” Certain drugs that block specific enzymes can help treat prostate diseases.
October 2015 in “Elsevier eBooks” Finasteride helps hair growth and prostate issues but may cause sexual side effects and increase tumor risk.
42 citations
,
May 2003 in “Mini-reviews in Medicinal Chemistry” New steroidal compounds could be effective for treating conditions related to 5α-reductase enzyme activity.
4 citations
,
April 2009 in “Journal of Pain” Finasteride boosts morphine's pain relief and prevents tolerance and withdrawal in rats.
173 citations
,
July 2012 in “British Journal of Dermatology” Dabrafenib can cause skin growths and sometimes low-grade skin cancer.
September 2010 in “European Urology Supplements”
These medications for BPH have known risks and may have new side effects.
22 citations
,
January 2018 in “European urology focus” New drugs and combination therapies are improving treatment for lower urinary tract symptoms.
57 citations
,
July 2016 in “The Journal of Sexual Medicine” 5α-reductase inhibitors increase the risk of sexual dysfunction, especially in men with enlarged prostate.
October 2021 in “Meditsinskiy sovet = Medical Council” Cyproterone acetate improves skin symptoms and quality of life in women with androgen-related issues.
3 citations
,
July 2022 in “BMC chemistry” The methods accurately measure finasteride and tadalafil in Entadfi™ capsules for quality control.
30 citations
,
October 2020 in “Nature Communications” Finasteride irreversibly affects human steroid 5α-reductase 2, providing insight into its catalytic mechanism and disease-related mutations.
30 citations
,
June 2010 in “Endocrine Related Cancer” SRD5A1 is crucial in advanced prostate cancer, and blocking both SRD5A1 and SRD5A2 is more effective than targeting SRD5A2 alone.
3 citations
,
February 2022 in “Rheumatology” Baricitinib was effective in treating a patient with dermatomyositis and hair loss.
26 citations
,
January 2005 in “PubMed” RUM-loaded SLN shows promise for treating acne and hair loss topically.